Blue Sail Medical Co.Ltd(002382)
Financial statement report of 2021
1、 Scope of consolidated statements and audit of financial statements of the company in 2021
(I) changes in the scope of consolidated statements
During the reporting period, in January 2021, Gaoge medical products (Hubei) Co., Ltd. and Lange Medical Technology (Hubei) Co., Ltd., wholly-owned subsidiaries of Wuhan bikele rescue products Co., Ltd., were newly established in Wuhan, Hubei Province, China.
In March 2021, NVT NVT sales GmbH absorbed biosensors Deutschland GmbH, a subsidiary within the merger scope, and changed its name to biosensors international Deutschland GmbH; Biosensors Iberia and SL respectively absorbed and merged NVT Productos cardiovasculares, s.l., a subsidiary within the consolidation scope.
In May 2021, Bosheng medical equipment (Shenzhen) Co., Ltd., a wholly-owned subsidiary of the company, was cancelled.
In July 2021, Shandong Baisheng Medical Equipment Co., Ltd., a wholly-owned subsidiary of the company, was cancelled.
In August 2021, the company’s wholly-owned subsidiary Blue Sail Medical Co.Ltd(002382) (Shanghai) Co., Ltd. was newly established in Shanghai, China, the company’s wholly-owned subsidiary lanfan (Hainan) supply chain Co., Ltd. was newly established in Hainan Province, China, and the company’s wholly-owned subsidiaries Zibo lanfan new materials Co., Ltd. and Zibo lanfan Health Technology Co., Ltd. were newly established in Zibo City, Shandong Province, China.
In December 2021, Shanghai Chengrui Medical Technology Co., Ltd., a wholly-owned subsidiary of Wuhan bikele rescue products Co., Ltd., a subsidiary of the company, was cancelled.
(II) audit of financial statements
The company’s 2021 financial statements and notes to relevant statements have been audited by Ernst & Young Huaming Certified Public Accountants (special general partnership) and issued an unqualified audit report of Ernst & Young Huaming (2022) Shen Zi No. 61519262j01. It is considered that the company’s financial statements are prepared in accordance with the accounting standards for business enterprises in all major aspects, It fairly reflects the financial position of the company’s merger and parent company as of December 31, 2021, and the operating results and cash flow of the merger and parent company in 2021.
2、 Main financial data and indicators
Unit: Yuan
Remarks on the increase or decrease of the project from 2021 to 2020 over the previous year
Operating income (yuan): 810858646473786942514432 3.04%
Net profit attributable to shareholders of listed companies 115570919119175847725529 – 34.28%
Deductions attributable to shareholders of listed companies not included in note 16212515370174182655980 – 96.43%
Net profit of recurring profit and loss
Net cash flow from operating activities 224554573613367153599649 – 38.84%
Basic earnings per share (yuan / share) 1.13 1.82 -0.69
Diluted earnings per share (yuan / share) 1.10 1.73 -0.63
Weighted average return on net assets 10.32%, 19.31% – 8.99%
Increase or decrease in remarks at the end of 2021 compared with the end of last year
Total assets 16913875507521703477795942 – 0.71%
Net assets attributable to shareholders of listed companies 1053628738273981720639325 7.32%
Note 1: the net profit attributable to shareholders of listed companies decreased by 34.28% in the current period compared with the same period of last year, the net profit attributable to shareholders of listed companies after deducting non recurring profits and losses decreased by 96.43% in the current period compared with the same period of last year, and the net cash flow from operating activities decreased by 38.84% in the current period compared with the same period of last year, mainly due to the repeated impact of China’s centralized procurement and foreign epidemic situations in the reporting period, as well as the downward trend in the price of health protection gloves, And the price of raw materials continues to fluctuate significantly.
3、 Financial situation analysis
(I) changes in assets
Unit: Yuan
Remarks on year-on-year increase and decrease of the project at the end of 2021 and 2020
Trading financial assets 6452260808297251744494 – 33.65% note 2
Receivables financing 620 China High-Speed Railway Technology Co.Ltd(000008) 243040 652.15% note 3
Prepayment 589819081619105400183 – 69.13% note 4
Other receivables 72117205914456462410 61.83% note 5
Inventory 11245363552176876824847 46.28% Note 6
Non current assets due within one year 4000000000 0.00 100.00% note 7
Other current assets 7833433893829556734454 165.03% note 8
Total current assets 634127120634717963147016 – 11.68%
Long term receivables 2322032389 0.00 100.00% note 9
Remarks on year-on-year increase and decrease of the project at the end of 2021 and 2020
Long term equity investment 302011944414772437266 104.44% note 10
Investment in other equity instruments 11106920027207200484 – 99.59% note 11
Fixed assets 45505799374422131687443 105.79% note 12
Construction in progress 8815531812825755793273 242.27% note 13
Right of use assets 4629123425 100.00% note 14
Development expenditure 482272604429934989598 – 83.89% note 15
Goodwill 351153577572541240540973 -35.12% note 16
Long term deferred expenses 122075698894603675104 165.17% note 17
Other non current assets 1347888789224746130446 – 45.53% note 18
Total non current assets 1057260430118985514648926 7.28%
Total assets 16913875507521703477795942 – 0.71%
Note 2: trading financial assets decreased by 33.65% at the end of the period compared with the beginning of the period, mainly due to the expiration of financial products during the reporting period; Note 3: accounts receivable increased by 652.15% at the end of the financing period compared with the beginning of the period, which was caused by the fact that the bank acceptance of goods sold in the reporting period was not yet due; Note 4: the prepayment at the end of the reporting period decreased by 69.13% compared with that at the beginning of the reporting period, mainly due to the decrease of prepayment for raw materials at the end of the reporting period; Note 5: other receivables increased by 61.83% at the end of the period compared with the beginning of the period, mainly due to the increase of deposit and margin receivable at the end of the reporting period; Note 6: the inventory at the end of the period increased by 46.28% compared with the beginning of the period, mainly due to the increase of production capacity, reserve raw materials and production inventory goods in the reporting period; Note 7: non current assets due within one year increased by 100.00% at the end of the period compared with the beginning of the period, mainly due to the reclassification of long-term receivables due within one year; Note 8: other current assets increased by 165.03% at the end of the period compared with the beginning of the period, mainly due to the purchase of non redeemable time deposits in the reporting period; Note 9: long term receivables increased by 100.00% at the end of the period compared with the beginning of the period, mainly due to the reclassification of accounts receivable in installments with a receivable period of more than one year in the reporting period; Note 10: long term equity investment increased by 104.44% at the end of the period compared with the beginning of the period, mainly due to the new investment in associates in the reporting period; Note: 11: the investment in other equity instruments decreased by 99.59% at the end of the period compared with the beginning of the period, mainly due to the investment in hainaruixin (Zibo) medical investment partnership (limited partnership) listed as “trading financial assets” in the reporting period;
Note 12: fixed assets increased by 105.79% at the end of the period compared with the beginning of the period, mainly due to the putting into use of “200 million pairs / year medical latex gloves”, “7.5 billion pieces / year health protection (new gloves) project” and “high-end health protection nitrile gloves project (phase I)”; Note 13: the construction in progress increased by 242.27% at the end of the period compared with the beginning of the period, mainly due to the new health protection glove production line project in the reporting period;
Note 14: the right of use assets increased by 100.00% at the end of the period compared with the beginning of the period, mainly due to the application of the new leasing standards since January 1, 2021 in the reporting period;
Note 15: the development expenditure at the end of the period decreased by 83.89% compared with the beginning of the period, which is mainly due to the full provision for impairment of the development expenditure of biofreedom products in the U.S. market in the reporting period;
Note 16: goodwill at the end of the period decreased by 35.12% compared with the beginning of the period, mainly due to the provision for impairment of goodwill of CB cardioholdings II Limited and CB cardioholdings V limited asset groups in the reporting period;
Note 17: the long-term deferred expenses increased by 165.17% at the end of the period compared with the beginning of the period, mainly due to the increase of new health protection glove production line projects in the reporting period; Note 18: other non current assets decreased by 45.53% at the end of the period compared with the beginning of the period, mainly due to the arrival of prepaid equipment for projects under construction in the reporting period.
(II) changes in liabilities and owner’s equity
Unit: Yuan
Remarks on year-on-year increase and decrease of the project at the end of 2021 and 2020
Short term loan
